Evaluation du rôle des co-transporteurs sodium-glucose SGLT1 et 2 dans l'induction de la sénescence et de la dysfonction des cellules endothéliales à l'aide d'une approche in vitro et in vivo
Abstract
Sodium-glucose cotransporter (SGLT)2 inhibitors have shown remarkable cardiovascular protective effects with reduced risk of cardiovascular mortality and hospitalization for heart failure in T2DM patients with a high cardiovascular risk and that this effect is independent of glucose control. The possibility that SGLT1 and 2 inhibitors protect the cardiovascular system by targeting the pivotal protective endothelial function remains unclear. The first in vitro study indicates that angiotensin II and circulating microparticles from patients with coronary artery disease via the activation of the local angiotensin system are potent inducers of SGLT1 and 2 expression to promote endothelial senescence and dysfunction. The second in vivo study indicates that the selective SGLT2 inhibitor empagliflozin protects the heart and the vascular system, and that the treatment is particularly effective to delay premature vascular senescence known to promote the development of cardiovascular diseases at arterial sites at risk of atherogenesis. Altogether, these studies suggest that inhibition of SGLT2 and/or SGLT1 might be an attractive therapeutic strategy to protect the endothelial function, and the subsequent development of cardiovascular diseases.
How strong is the evidence?
Evidence Hub reads this as a thesis, done in animal and cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.